-+ 0.00%
-+ 0.00%
-+ 0.00%

Brooks Laboratories' (NSE:BROOKS) Earnings Are Built On Soft Foundations

Simply Wall St·11/15/2026 02:03:09
Listen to the news

Solid profit numbers didn't seem to be enough to please Brooks Laboratories Limited's (NSE:BROOKS) shareholders. Our analysis suggests they may be concerned about some underlying details.

earnings-and-revenue-history
NSEI:BROOKS Earnings and Revenue History November 15th 2026

Examining Cashflow Against Brooks Laboratories' Earnings

One key financial ratio used to measure how well a company converts its profit to free cash flow (FCF) is the accrual ratio. In plain english, this ratio subtracts FCF from net profit, and divides that number by the company's average operating assets over that period. The ratio shows us how much a company's profit exceeds its FCF.

Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. While having an accrual ratio above zero is of little concern, we do think it's worth noting when a company has a relatively high accrual ratio. Notably, there is some academic evidence that suggests that a high accrual ratio is a bad sign for near-term profits, generally speaking.

Over the twelve months to September 2026, Brooks Laboratories recorded an accrual ratio of 0.58. Ergo, its free cash flow is significantly weaker than its profit. As a general rule, that bodes poorly for future profitability. To wit, it produced free cash flow of ₹1.1m during the period, falling well short of its reported profit of ₹728.4m. Brooks Laboratories shareholders will no doubt be hoping that its free cash flow bounces back next year, since it was down over the last twelve months. Having said that, there is more to the story. We can see that unusual items have impacted its statutory profit, and therefore the accrual ratio.

View our latest analysis for Brooks Laboratories

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Brooks Laboratories.

How Do Unusual Items Influence Profit?

Given the accrual ratio, it's not overly surprising that Brooks Laboratories' profit was boosted by unusual items worth ₹750m in the last twelve months. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. And, after all, that's exactly what the accounting terminology implies. Brooks Laboratories had a rather significant contribution from unusual items relative to its profit to September 2026. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

Our Take On Brooks Laboratories' Profit Performance

Brooks Laboratories had a weak accrual ratio, but its profit did receive a boost from unusual items. On reflection, the above-mentioned factors give us the strong impression that Brooks Laboratories'underlying earnings power is not as good as it might seem, based on the statutory profit numbers. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. To help with this, we've discovered 3 warning signs (1 doesn't sit too well with us!) that you ought to be aware of before buying any shares in Brooks Laboratories.

In this article we've looked at a number of factors that can impair the utility of profit numbers, and we've come away cautious. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.